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Summary
Objectives: The aim of this studywas to enhance tuberculosis (TB) treatment outcomemonitoring
by linking diverse surveillance systems and estimating treatment outcomes including relapse.
Methods: Tuberculosis treatment was surveyed in the Lazio region (Italy) from 1999 to 2001; a six-
year follow-up of notified cases was undertaken to detect relapses. The results were analyzed as a
population-based case—control study comparing each unsuccessful outcome and relapse with
eligible controls.
Results: Of the 974 patients who entered the survey, 805 (82.6%) had complete treatment
evaluations; 398 (49.4%) had a successful outcome, 401 (49.8%) had an unsuccessful outcome,
and six developed chronic TB. Death was associated with age>64 years (OR 5.9; 95% CI 3.1—11.2),
male gender (OR 2.1; 95% CI 1.0—4.4), and using second-line drugs (OR 2.3; 95% CI 1.0—5.4).
Treatment failure was associated with previous treatment (OR 3.0; 95% CI 1.4—6.7) and being
male, being foreign born (OR 6.6; 95% CI 2.1—21.2), receiving second-line drugs (OR 7.4; 95% CI
1.8—29.5), and receiving modified therapy (OR 5.1; 95% CI 1.7—14.9). Relapses after successful
outcomes were detected in 5.5%, for which the strongest predictor was having extrapulmonary
lesions (OR 22.8; 95% CI 1.8—287.3).
Conclusions: Linking our survey data to other surveillance systems improved the mortality esti-
matesanddetectedahigh rateof relapse.Having receivedprevious treatmentandbeinga foreigner
were independent determinants of treatment failure, suggesting that both acquired and primary
drug resistance affect TB patients in Lazio.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Introduction
Treatment surveillance is an essential tool in the evaluation
of the impact of tuberculosis (TB) control programmes,1
especially for multi-drug resistant tuberculosis (MDR-TB).2
Early detection and adequate treatment are the most impor-
tant tools to control MDR-TB. Successful treatment interrupts
the transmission of infection, which prevents additional
cases of acquired MDR-TB and avoids the development of
chronic or recurrent TB. MDR-TB can be either the conse-
quence of or be caused by unsuccessful treatment, which
may occur by transmission of an MDR strain ofMycobacterium
tuberculosis or following inadequate treatment.3—6 Both
situations challenge tuberculosis control, because standar-
dized short-course chemotherapy (SSCC) is less effective in
these patients, and second-line drugs are less effective and
more toxic than first-line drugs.7
As with other surveillance systems, validity issues may
affect TB treatment surveillance, made worse by the lengthy
treatment required. While many studies report results of
treatment surveillance, most do not use data from other
sources to test the accuracy of TB treatment outcomes.
Further, most surveillance systems do not include long-term
outcomes such as relapses, because the follow-up period is
too short. Among those with recurrent TB, relapse represents
the reactivation of a latent infection.6,8
This study aimed to improve the accuracy of a TB treat-
ment survey by linking the information to other surveillance
systems, to estimate TB relapses in the six years after initial
notification, and to analyze risk factors for unsuccessful
treatment outcomes.
Methods
We surveyed TB treatment outcomes in residents of the Lazio
region of Italy (5 255 028 inhabitants), reported to the TB
surveillance system for pulmonary TB, who began treatment
between 1 January 1999 and 31 December 2001. Only new or
relapsed cases were included. Patients infected with Myco-
bacterium bovis and Mycobacterium avium were excluded.
Active follow-up of treatment outcomes lasted for at least 12
months after treatment began, and ended on 31 December
2002. In addition, we looked for deaths of TB patients in the
regional cause-mortality register (CMR). Relapses in patients
who started treatment in the period 1999—2001 were
detected by linking our data with the infectious diseases
notification registry (IDNR) and the hospital discharge reg-
istry (HDR). This linkage was conducted between 1 January
2000 and 31 December 2005.
TB treatment survey
All public and private hospitals and outpatient clinics in the
region that had reported at least two TB cases per year
participated in the survey. TB therapy units were asked to
complete a form for each new or relapsed case of pulmonary
TB at the beginning and end of treatment. Initial information
included patient category according to World Health Orga-
nization (WHO) classification,2,4,5,9 drugs prescribed, and
length of therapy. New cases were defined as patients who
had never been treated for tuberculosis for one month or
more. Relapsed patients were those who had had previous
successful treatment. Treatment failures were patients with
a positive sputum smear at 5months or later after the start of
treatment. Defaulters were those who returned to treatment
after an interruption of at least two months. Transfers-in had
been transferred from one clinic to another and continued
treatment without interruption.
The entire treatment history was reconstructed from the
initial visit for TB to the treatment outcome reported from
the last TB unit that treated the patient. Patient category
was considered ‘unknown’ for transfers-in.
One treatment outcome was assigned to each TB case in
the survey based on their last end-of-treatment form. Treat-
ment outcomewas considered unknown if the TB units did not
complete the final treatment form.
Case definition
For the purposes of the case—control study, a case was
defined as a new or relapsed patient diagnosed by sputum
culture, smear examination for acid-fast bacilli, or X-rays,
who was unsuccessfully treated in the survey. The unsuccess-
ful outcomes were classified according to WHO proto-
col:2,4,5,9 (1) death for any reason during treatment, (2)
treatment failure or default, and (3) lost to follow-up. In
our survey this group corresponded to patients transferred-
out from one TB clinic to another to continue treatment.
Since we reconstructed the entire treatment history of each
patient, we know that this last group included patients who
did not return to the same clinic or contact another clinic in
the region to complete treatment. Cases reported in the CMR
were included as fatal outcomes if death occurred within
nine months of the start of therapy. Patients who re-pre-
sented with bacteriologically positive disease more than
three months after a successful outcome,2,6 who had not
received treatment prior to the first notification,10 and who
were still alive 12 months after therapy started6 were clas-
sified as relapses.
Control definition
Controls for each outcome (death, failure, lost) were
selected from successfully treated TB patients or those
who had a different unsuccessful outcome. Controls had to
meet the same criteria as cases to be included, namely they
had to be new or relapsed TB cases and residents of the
region, who had started treatment in the period 1999—2001.
Successful treatment was defined, as suggested by the
WHO,2,4,5,9 as having a microbiologically negative test at
least two months after treatment began or at treatment
completion.
Controls for relapses were patients who did not re-present
with bacteriologically diagnosed TB by the end of follow-up,
who had had a successful outcome, had received no prior
treatment before the initial notification, and were still alive
12 months after treatment began.
Factors analyzed
The factors analyzed as possible predictors of unsuccessful
outcomes or relapses were related to characteristics of the
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infection or patient management. Characteristics of infec-
tion included: age, gender, foreign status (according to birth
country and/or nationality), urban versus suburban resi-
dence, notification year, HIV status, patient category, pre-
vious treatment, site of the tuberculosis lesions, and results
of the smear test. The factors related to patientmanagement
were: drugs, therapy length andmodification, and transfer to
another TB clinic during treatment. Educational level was
used as an indicator of social class.
First-line drugs were classified according to the WHO
protocol1 and included isoniazid and/or rifampin and/or
pyrazinamide and/or ethambutol with or without strepto-
mycin.
Analyses
Univariate analyses compared each of the three types of
unsuccessful outcomes (death, failure and defaulter, lost to
follow-up) with all other patients who did not have that
specific outcome, including those successfully treated and
those with the other unsuccessful outcomes. Relapses were
compared with patients at risk of relapse but who had not
done so by the end of 2005. Odds ratios (OR) with 95%
confidence intervals (CI) were calculated. The role of each
variable was explored using logistic regression, in terms of
how it may have confounded or modified the effect of the
foreign status on unsuccessful outcomes.
Multivariate models included all variables showing a uni-
variate association and a level of statistical significance of
0.1 or less. The likelihood ratio test (LRT) was used to select
the final models. STATA software (version 8, STATA Corp., TX,
USA) was employed for the analysis.
Results
Treatment forms were completed for 789 of 974 TB patients
included in the survey. Another 16 patients had therapy
outcomes reported by other surveillance systems. We had
complete information for 805 (82.6%) patients; six of them
were later recognized as chronic TB patients on the basis of
previous hospitalization history and were excluded from the
analysis.
Patients included in the study (N = 799) were more likely
to be male and to have been reported in the first year of the
study. They were more likely to have positive smear tests or
lesions exclusively in the respiratory tract. There were more
patients with higher education included than excluded
(18.0% and 9.5%), but this was not analyzed further due to
the large amount of missing information (Table 1). Treatment
profiles show that patients included in the study were less
seriously ill. Those included were more likely to have been
given first-line drugs (90.9% vs. 82.3%), been treated for six
months (63.0% vs. 52.7%), and to have been transferred to
outpatient clinics (9.9% vs. 4.1%).
Among the 799 patients with complete outcome informa-
tion, there were 401 unsuccessfully treated cases: 55 deaths
(6.9%), 16 treatment failures (2.0%), 20 defaulters (2.5%),
and 310 (38.8%) transferred-out from a single unit/lost to
follow-up. Twenty-three deaths (41.8%) were reported in the
CMR. These patients had received different outcome classi-
fications in the TB treatment surveillance: three had been
reported as successful outcome, four as transferred-out, six
as lost to follow-up, and 10 as unknown outcome. There were
398 successfully treated patients (49.8%), 179 were cured
and 219 completed treatment.
Pulmonary TB cases were categorized at the beginning of
treatment as new (81%), relapses (7%), or previously treated
who had failed or interrupted treatment (4%); 8% of cases
were transferred-in to a study clinic and their initial category
could not be assessed. Treatment lasted longer than six
months for 25% of patients and 9% were given second-line
drugs. The majority of patients (87%) started and completed
treatment at the same clinic, 10% were transferred to an
outpatient clinic, and 3% to another hospital.
Twenty relapses (5.5%) occurred after successful treat-
ment among those successfully treated for the first TB epi-
sode (n = 360). A mean interval of 32 months elapsed
between starting therapy and the relapse (range 12—74
months).
The risk of dying during TB treatment was higher for
patients aged over 64 years, males and those treated with
second line drugs; foreigners had lower risk (Table 2).
Failures/defaulters were more likely to have been pre-
viously treated. Males whose treatment failed were more
likely to be foreigners, to have been given second-line
drugs, or to have had their therapy modified, as shown
in the final model (Table 3). Those lost to follow-up were
more likely to be foreign-born, whereas modified treat-
ment or being transferred to an outpatient clinic showed a
protective effect for this outcome, as shown in the final
model (Table 4).
Nationality was reported for 257 (95.9%) out of the 285
patients classified as foreign. Among all foreigners, patients
from Southeast Asia (OR 13.62; 95% CI 1.12—94.52) and
Eastern Europe (OR 7.57; 95% CI 1.75—29-56) had the highest
risk of having a negative outcome.
TB relapses were more frequent among patients aged 35—
64 years (50%) and males (70%). After adjusting for other
variables, the risk of relapse was even higher for patients who
had extrapulmonary lesions. Those who had been treated for
more than six months and those who had modified the
treatment were at higher risk of relapse, though the results
were not statistically significant (Table 5).
Discussion
Links with other surveillance systems
The use of record-linkage to the cause-mortality register
allowed us to detect 23 more deaths than reported to the
TB treatment surveillance. Among these, 10 were excluded
because TB treatment forms were not completed and the
outcome was unknown; another ten were classified in the
surveillance as transfer-out or lost to follow-up. The record-
linkage to the hospital discharge register identified six
chronic TB cases that had to be excluded from the TB
treatment surveillance. These results give an estimate of
the possible misclassification of incident TB cases and suggest
that incomplete treatment surveillance may be due to
patient death.
Routinely linking different systems is an unlikely solution
to improve TB treatment surveillance, but these procedures
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Table 1 Cases of pulmonary TB included and not included in the case—control study by demographic and clinical factors; Lazio,
1999—2001
Factors Cases
Entered survey
(N = 968)
With known
outcome (N = 799)
With unknown outcome
(N = 169)
n % n % n % p-Valuea
Age (years) 0.43
<14 31 3.2 22 2.8 9 5.3
15—34 356 36.8 296 37.0 60 35.5
35—64 402 41.5 331 41.4 71 42.0
65+ 176 18.2 148 18.5 28 16.6
MIb 3 0.3 2 0.3 1 0.6
Gender 0.002
M 614 63.4 516 64.6 98 58.0
F 315 32.5 259 32.4 56 33.1
MIb 39 4.0 24 3.0 15 8.9
Foreign status 0.03
No 608 62.8 514 64.3 94 55.6
Yes 360 37.2 285 35.7 75 44.4
MIb 0
Residence 0.02
Rome 562 58.1 480 60.1 82 48.5
Other cities/towns 375 38.7 295 36.9 80 47.3
MIb 31 3.2 24 3.0 7 4.1
Notification year 0.001
1999 378 39.0 336 42.1 42 24.9
2000 307 31.7 220 27.5 87 51.5
2001 283 29.2 243 30.4 40 23.7
Previous treatment 0.74
No 785 81.1 645 80.7 140 82.8
Yes 100 10.3 83 10.4 17 10.1
MIb 83 8.6 71 8.9 12 7.1
HIV status 0.33
Positive 21 2.2 19 2.4 2 1.2
Negativec 947 97.8 780 97.6 167 98.8
TB site 0.001
Pulmonary 724 74.8 630 78.8 94 55.6
Pulm.+ extrapulm. 47 4.9 37 4.6 10 5.9
MIb 197 20.4 132 16.5 65 38.5
Smear 0.001
Positive 580 59.9 508 63.6 72 42.6
Negativec 189 19.5 157 19.6 32 18.9
MIb 199 20.6 134 16.8 65 38.5
Education (years) 0.001
1—8 349 36.1 312 39.0 37 21.9
9—17 160 16.5 144 18.0 16 9.5
MIb 459 47.4 343 42.9 116 68.6
a p-Value has been tested by comparing the distribution of not included cases who did not start therapy and who did not finish the survey to
that of included cases separately.
b Missing information.
c Including ‘not known’ results.
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Table 2 Risk of dying during treatment of TB pulmonary; Lazio, 1999—2001
Factors Death Crude Adjusted
Yes (N = 55) No (N = 744) OR 95% CI OR 95% CI
Age (years)
<65 21 606 1
65+ 34 114 8.61 4.82—15.37 5.92 3.14—11.19
MIa 0 24
Gender
F 12 247 1
M 43 473 1.87 0.97—3.61 2.06 0.98—4.36
MIa 0 24
Foreign status
No 52 462 1
Yes 3 282 0.09 0.03—0.31 0.16 0.04—0.72
MIa 0 0
Residence
Rome 30 450 1
Other towns 24 271 1.33 0.76—2.32
MIa 1 23
Previous treatment
No 43 602 1
Yes 10 73 1.92 0.92—3.98 1.28 0.55—2.98
MIa 2 69
HIV status
Nob 55 725 1
Yes 0 19 NC
Smear
Negativec 7 150 1
Positive 37 471 1.68 0.74—3.85
MIa 11 123
Prescribed drugs
First line 44 682 1
Second line 11 62 2.75 1.32—5.59 2.34 1.02—5.37
MIa 0 0
Length of therapy
6 months 32 471 1
7 months 13 183 1.04 0.54—2.04
MIa 10 90
Modified therapy
No 19 333 1
Yes 5 137 0.64 0.23—1.75
MIa 31 274
Transferred to:
No other clinic 54 642 1
Out-patient clinic 0 79 NC
Another hospital 1 20 0.59 0.08—4.51
MIa 0 3
NC = not computable.
a Missing information.
b Including ‘not known’ results.
c Case confirmed only by X-ray test or by tuberculin test or with ‘not known’ smear result.
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Table 3 Risk of failure or defaulter therapy for TB pulmonary cases; Lazio, 1999—2001
Factors Failure or defaulter Females Males
Yes (N = 36) No (N = 763) OR 95% CI Adj. OR 95% CI Adj. OR 95% CI
Agea (years)
35—64 31 596 1
65+ 5 143 0.67 0.24—1.76
MIb 0 24
Gender
F 9 250 1
M 27 489 1.53 0.71—3.31
MIb 0 24
Foreign status
No 19 495 1
Yes 17 268 1.65 0.31—1.19 0.69 0.06—7.55 6.63 2.08—21.16
MIb 0 0
Residence
Rome 25 455 1
Other towns 10 285 0.64 0.30—1.35
MIb 1 23
Previous treatment
No 25 620 1
Yes 9 74 3.01 1.36—6.71 2.43 0.19—30.84 1.09 0.27—4.34
MIb 2 69
HIV status
Noc 36 750 1
Yes 0 19 NC
Smear
Negatived 4 153 1
Positive 27 481 2.15 0.74—6.23
MIb 5 129
Prescribed drugs
First line 25 701 1
Second line 11 62 4.97 2.34—10.59 4.05 0.29—55.92 7.37 1.84—29.45
MIb 0 0
Length of therapy
6 months 26 477 1
7 months 7 189 0.68 0.29—1.59
MIb 3 97
Modified therapy
No 9 343 1
Yes 14 128 4.17 1.76—9.87 1.46 0.16—13.37 5.07 1.72—14.94
MIb 13 292
Transferred to:
No other clinic 30 666 1
Out-patient clinic 4 75 1.18 0.41—3.45
Another hospital 2 19 2.34 0.52—10.50
MIb 0 3
NC = not computable.
a Odds ratios of dying were calculated for cases aged 65+ years vs. those aged 35—64 years because there were no TB cases younger than 35
years.
b Missing information.
c Including ‘not known’ results.
d Case confirmed only by X-ray test or by tuberculin test or with ‘not known’ smear result.
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Table 4 Risk of being lost to therapy follow-up for TB pulmonary cases; Lazio, 1999—2001
Factors Lost to follow-up Crude OR 95% CI Adj. OR 95% CI
Yes (N = 310) No (N = 489)
Agea (years)
0—14 4 18 1
15—34 132 164 3.62 1.20—10.96
35—64 134 197 3.06 1.01—9.25
65+ 39 109 1.61 0.51—5.05 0.85 0.46—1.59
MIb 1 1
Gender
F 94 165 1
M 200 316 1.11 0.82—1.51 1.46 0.89—2.38
MIb 16 8
Foreign status
No 160 354 1
Yes 150 135 2.45 1.82—3.31 3.48 2.11—5.74
MIb 0 0
Residence
Rome 198 282 1
Other towns 101 194 0.74 0.55—1.00
MIb 11 13
Previous treatment
No 260 385 1
Yes 28 55 0.75 0.47—1.22
MIb 22 49
HIV status
Noc 301 479 1
Yes 9 10 1.43 0.58—3.57
Smear
Negatived 63 94 1
Positive 198 310 0.95 0.66—1.37
MIb 49 85
Prescribed drugs
First line 286 440 1
Second line 24 49 0.75 0.45—1.26
MIb 0 0
Length of therapy
6 months 189 314 1
7 months 61 135 0.75 0.53—1.07
MIb 60 40
Modified therapy
No 140 212 1
Yes 14 128 0.17 0.09—0.30 0.17 0.09—0.32
MIb 156 155
Transferred to:
No other clinic 299 397 1
Out-patient clinic 1 78 0.02 0.002—0.12 0.02 0.003—0.1
Another hospital 8 13 0.82 0.33—2.00 1.06 0.32—3.57
MIb 2 1
a Adjusted odds ratios were calculated for cases aged 65+ years vs. those aged 0—64 years.
b Missing information.
c Including ‘not known’ results.
d Case confirmed only by X-ray test or by tuberculin test or with ‘not known’ smear result.
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Table 5 Risk of relapsing for TB pulmonary cases in treatment surveillance; Lazio, 1999—2001
Factors Relapse Crude OR 95% CI Adj. OR 95% CI
Yes (N = 20) No (N = 340)
Agea (years)
0—14 1 17 1
15—34 7 132 0.90 0.10—7.78
35—64 10 132 1.29 0.16—10.69
65+ 2 58 0.59 0.05—6.87
MIb 0 1
Gender
F 6 126 1
M 14 206 1.43 0.53—3.81 1.98 0.30—12.83
MIb 0 8
Foreign status
No 15 241 1
Yes 5 99 0.81 0.29—2.29 0.14 0.01—1.83
MIb 0 0
Residence
Rome 14 195 1
Other towns 5 137 0.51 0.18—1.44 0.16 0.02—1.60
MIb 1 8
HIV status
Noc 20 330 1
Yes 0 10 NC
TB site
Pulmonary 14 271 1
Pulm. + extrapulm. 3 12 4.84 1.22—19.13 22.84 1.82—287.3
MIb 3 57
Smear
Negatived 4 76 1
Positive 13 205 1.20 0.38—3.81
MIb 3 59
Prescribed drugs
First line 20 319 1
Second line 0 21 NC
MIb 0 0
Length of therapy
6 months 11 228 1
7 months 6 89 1.49 0.57—3.92 5.46 0.71—41.74
MIb 3 23
Modified therapy
No 5 168 1
Yes 7 85 2.77 0.85—8.98 4.54 0.61—33.61
MIb 8 87
Transferred to:
No other clinic 16 268 1
Out-patient clinic 3 63 0.80 0.23—2.82
Another hospital 0 9 NC
MIb 1 0
NC = not computable.
a Adjusted odds ratios were calculated for cases aged 65+ years vs. those aged 0—64 years.
b Missing information.
c Including ‘not known’ results.
d Case confirmed only by X-ray test or by tuberculin test or with ‘not known’ smear result.
could be carried out from time to time for patients with no
information on treatment outcome.
The unknown TB treatment outcomes
Up until 2000, patients lost to follow-up and transferred-out
were not usually included in analyses of unsuccessful treat-
ment.11—14 However, other authors classify these outcomes
as treatment interruption.15—17 There is a large range in the
estimates of patients lost to follow-up in the literature: in
some countries values of 20—24% have been reported,18—20
while in others the estimates are 4—8%,13,21 suggesting pos-
sible differences in interpreting the WHO definitions. Mod-
ifications were introduced in 2001 in the WHO European
region to overcome this problem, and countries were
requested to monitor cases with unknown treatment his-
tory.5,22
We included both transfer-out and lost to follow-up in our
survey and analyzed them together because our hypothesis
was that both groups were less likely to complete therapy. A
recent paper that tracked the modifications introduced in
Europe in 2001 strengthens this belief, showing that
‘defaulted and transferred’ were applied interchangeably
with ‘unknown’ outcomes.22
On the other hand, monitoring unknown outcomes is not
easy due to a lack of treatment information. We decided to
exclude from the analysis those patients for whom only the
first form was completed when there was no more informa-
tion from other sources, but to include patients who had later
information reported by the TB unit with outcomes such as
transferred or lost to follow-up. Although these outcomes do
not allow a final judgment on the entire course of treatment,
they do provide more information about the first months of
treatment.
Factors associated with unsuccessful treatment
outcomes
Death
Age was the strongest factor associated with death during
treatment. More fatal outcomes were reported in Europe
(5.8%) than in other parts of the world in 2000.23 In our study,
patients born in Italy made up 94% of the fatalities, possibly
explained by their older age (mean 64.6 years vs. 45.4 years
among foreigners who died). None of the patients who died
were known to be HIV positive.
The higher risk of death for patients treated with second-
line drugs (20% of those who died vs. 9% of those who
survived) is coherent with the known higher toxicity these
drugs have compared with first-line drugs,7 and suggests the
patients were drug resistant.
Failures and defaulters
We included in this group those patients still in treatment at
the end of the six or nine months of standard course. The
surveillance system changed in 2001 and these patients were
defined with an independent outcome, but previously they
had been classified as ‘not evaluated by the end of the follow-
up’ and the outcomes were considered unknown.22 Our study
was inspired by the 1998 European WHO recommendations
that suggested reporting the outcome as failure when the
patient was still in treatment after six/nine months of treat-
ment, and attributing the category already treated to con-
tinue his/her treatment surveillance in this case.
The strength of the association between treatment failure
and second-line drugs in both female and male patients
suggests that MDR-TB is the cause. Previous treatment is a
clear predictor of an unsuccessful outcome.11,24 However, we
observed that previous treatment was weakly associated
with failure, and was observed only in female patients, while
being a foreigner and receiving second-line drugs were the
most important predictors of treatment failure in males. One
possible interpretation of these results is that males born
abroad have primary multi-drug resistance. The highest risk
of failure was observed in patients from Eastern Europe and
Southeast Asia, which is consistent with this hypothesis.
Although no differences were found between drugs pre-
scribed to non-Italians and Italians, other aspects of treat-
ment that were not analyzed here3,12,16,25,26 could have
made treatment inadequate in foreign-born patients.
A misclassification of previous treatment could also have
contributed to these results. Illegal immigrants are more
likely to deny previous treatment,27 and we observed a
higher risk of failure for foreign-born males, who more
frequently than females are illegal immigrants.
Loss to follow-up and transfer-out
The similar risk profiles observed in our study for both those
lost to follow-up and transfer-outs support the hypothesis
that the problems they faced were linked to patient manage-
ment.
The protective effect of outpatient clinic transfer and
modification of therapy suggests treatment retention,
although the conclusion should be made with caution
because the result may be due to reverse causation, i.e.,
patients who are less seriously ill are more likely to complete
treatment.
Relapse
Recurrent TB was considered relapse because information on
DNA fingerprints of the M. tuberculosis isolates was not
available. The absence of HIV-positive patients in this group
supports the relapse hypothesis. The percentages of relapses
observed in the study population (7%) and observed in the
follow-up period amongst new TB cases (5.5%) are higher
than those reported by WHO for Europe in 2003 (4%),23 but
consistent with the results of other trials.10 Higher estimates
of relapses (12% and 36%) have been reported in areas with
high drug resistance.28,29 The high risk of relapse for patients
with extrapulmonary lesions has not been previously
reported,30 and we are not able to explain this result. The
period of 3—6 months after treatment ended that we used as
the shortest interval to define a relapse is usually adopted in
successfully treated patients.6,10,29 Follow-ups of six years
have been increasingly adopted,31 probably because of data
availability.
Limitations of the study
The most important limitation of this study is a possible
selection bias due to the exclusion of those patients who
did not have any outcome information, which could have
prevented comparisons of important patient and treatment
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characteristics. Patients included did not differ for being a
foreigner, the factor in which we were most interested, or for
previous treatment. However, the generalizability of the
results may be affected by gender and severity of illness.
A second important limitation is the absence of data on
drug resistance that prevents us directly estimating its
impact on failure and relapse.
A national study project on TB treatment outcome in HIV
positive patients began in 2000, which may have reduced
compliance with the regional survey for these patients in the
second year of our study. The decrease over time in informa-
tion reported also suggests other reasons for poor compli-
ance, including difficulties in sustaining reporting over a long
time.
Conclusions
Linking TB outcomes with data from other surveillance sys-
temsmarkedly improved themortality estimates and allowed
us to detect recurrent cases of the disease. The ability to
accurately detect recurrent disease is a valuable addition to
current surveillance systems as an evaluation tool for TB
control programs.
Previous treatment and foreign status were independent
determinants of failure and default, and suggest the coex-
istence of both acquired and primary drug resistance in our
region. Some factors linked to patient management emerged
as risk factors for being lost to follow-up, suggesting diffi-
culties in access to health services for foreign-born patients.
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